{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T21:58:57Z","timestamp":1765231137846,"version":"build-2065373602"},"reference-count":131,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.clml.2019.08.011","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T19:17:11Z","timestamp":1567106231000},"page":"689-698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies"],"prefix":"10.1016","volume":"19","author":[{"given":"Alessandro","family":"Allegra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Innao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Gaetano","family":"Allegra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Leanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.08.011_bib1","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1016\/j.bbamcr.2014.08.003","article-title":"Macromolecular transport between the nucleus and the cytoplasm: advances in mechanism and emerging links to disease","volume":"1843","author":"Tran","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clml.2019.08.011_bib2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nature07975","article-title":"Structural basis for leucine-rich nuclear export signal recognition by CRM1","volume":"458","author":"Dong","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.clml.2019.08.011_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","article-title":"Atomic basis of CRM1-cargo recognition, release and inhibition","volume":"27","author":"Fung","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clml.2019.08.011_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","article-title":"Selective inhibitors of nuclear export (SINE)\u2014a novel class of anti-cancer agents","volume":"7","author":"Parikh","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2019.08.011_bib5","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1074\/jbc.R600026200","article-title":"Classical nuclear localization signals: definition, function, and interaction with importin alpha","volume":"282","author":"Lange","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2019.08.011_bib6","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1093\/emboj\/16.21.6535","article-title":"The asymmetric distribution of the constituents of the Ran system is essential for transport into and out of the nucleus","volume":"16","author":"Izaurralde","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.clml.2019.08.011_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.tcb.2005.01.005","article-title":"Leucine-rich nuclear-export signals: born to be weak","volume":"15","author":"Kutay","year":"2005","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.clml.2019.08.011_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.molcel.2004.11.018","article-title":"Architecture of CRM1\/exportin1 suggests how cooperativity is achieved during formation of a nuclear export complex","volume":"16","author":"Petosa","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.clml.2019.08.011_bib9","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.1074\/jbc.M111.334094","article-title":"HEAT repeat 1 motif is required for B56gamma-containing protein phosphatase 2A (B56gamma-PP2A) holoenzyme assembly and tumor-suppressive function","volume":"287","author":"Nobumori","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2019.08.011_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrc1274","article-title":"Nuclear transport and cancer: from mechanism to intervention","volume":"4","author":"Kau","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2019.08.011_bib11","first-page":"7","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"5","author":"Gravina","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2019.08.011_bib12","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","article-title":"Nuclear export of proteins and drug resistance in cancer","volume":"83","author":"Turner","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clml.2019.08.011_bib13","doi-asserted-by":"crossref","first-page":"38098","DOI":"10.1074\/jbc.M605271200","article-title":"Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via Cdk phosphorylation-dependent nuclear export","volume":"281","author":"Jiao","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2019.08.011_bib14","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/sj.onc.1208283","article-title":"Cell cycle\u2013dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin","volume":"24","author":"Muranen","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2019.08.011_bib15","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/emboj\/cdg105","article-title":"Nuclear export of the APC tumour suppressor controls beta-catenin function in transcription","volume":"22","author":"Rosin-Arbesfeld","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.clml.2019.08.011_bib16","doi-asserted-by":"crossref","first-page":"e0130610","DOI":"10.1371\/journal.pone.0130610","article-title":"Leukemia-associated mutations in nucleophosmin alter recognition by CRM1: molecular basis of aberrant transport","volume":"10","author":"Arregi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2019.08.011_bib17","doi-asserted-by":"crossref","first-page":"7701","DOI":"10.1074\/jbc.M111.327296","article-title":"Characterization of BRCA1 protein targeting, dynamics, and function at the centrosome: a role for the nuclear export signal, CRM1, and Aurora A kinase","volume":"287","author":"Brodie","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2019.08.011_bib18","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/ncb1638","article-title":"Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation","volume":"9","author":"Kanai","year":"2007","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.clml.2019.08.011_bib19","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4161\/cc.4.7.1796","article-title":"Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins","volume":"4","author":"Vogt","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clml.2019.08.011_bib20","doi-asserted-by":"crossref","first-page":"15053","DOI":"10.1074\/jbc.M200248200","article-title":"Nuclear import and export signals in control of the p53-related protein p73","volume":"277","author":"Inoue","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2019.08.011_bib21","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/emboj\/18.5.1223","article-title":"Apoptosis inhibitory activity of cytoplasmic p21(Cip1\/WAF1) in monocytic differentiation","volume":"18","author":"Asada","year":"1999","journal-title":"EMBO J"},{"key":"10.1016\/j.clml.2019.08.011_bib22","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.4161\/cc.6.24.5087","article-title":"Multiple mechanisms for p27(Kip1) translocation and degradation","volume":"6","author":"Susaki","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clml.2019.08.011_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yexcr.2003.12.016","article-title":"Regulation of subcellular localization of the antiproliferative protein Tob by its nuclear export signal and bipartite nuclear localization signal sequences","volume":"295","author":"Maekawa","year":"2004","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.clml.2019.08.011_bib24","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1128\/MCB.24.10.4395-4406.2004","article-title":"Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs","volume":"24","author":"Takenaka","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2019.08.011_bib25","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1073\/pnas.97.3.1014","article-title":"A\u00a0nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB\/IkappaBalpha complexes","volume":"97","author":"Huang","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2019.08.011_bib26","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.18632\/oncotarget.1339","article-title":"Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus","volume":"4","author":"Huang","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2019.08.011_bib27","first-page":"5747","article-title":"Changes in sub-cellular distribution of topoisomerase II alpha correlate with etoposide resistance in multicell spheroids and xenograft tumors","volume":"60","author":"Oloumi","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2019.08.011_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.celrep.2012.07.007","article-title":"The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation","volume":"2","author":"Culjkovic-Kraljacic","year":"2012","journal-title":"Cell Rep"},{"key":"10.1016\/j.clml.2019.08.011_bib29","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.3748\/wjg.v21.i42.12150","article-title":"Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy","volume":"21","author":"Ohkoshi","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clml.2019.08.011_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clml.2019.08.011_bib31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrc3539","article-title":"Forkhead box proteins: tuning forks for transcriptional harmony","volume":"13","author":"Lam","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2019.08.011_bib32","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1083\/jcb.200112059","article-title":"14-3\u20133 transits to the nucleus and participates in dynamic nucleocytoplasmic transport","volume":"156","author":"Brunet","year":"2002","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.clml.2019.08.011_bib33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1042\/bj3540605","article-title":"Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3\u20133 binding, transactivation and nuclear targetting","volume":"354","author":"Rena","year":"2001","journal-title":"Biochem J"},{"key":"10.1016\/j.clml.2019.08.011_bib34","doi-asserted-by":"crossref","first-page":"8969","DOI":"10.1128\/MCB.20.23.8969-8982.2000","article-title":"Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN","volume":"20","author":"Nakamura","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2019.08.011_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/B978-0-12-386469-7.00005-0","article-title":"TP53 mutations in human cancer: database reassessment and prospects for the next decade","volume":"110","author":"Soussi","year":"2011","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.clml.2019.08.011_bib36","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.1073\/pnas.89.15.7262","article-title":"Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion","volume":"89","author":"Moll","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2019.08.011_bib37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.onc.1203262","article-title":"Nuclear exclusion of p53 in a subset of tumors requires MDM2 function","volume":"19","author":"Lu","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2019.08.011_bib38","first-page":"545","article-title":"Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines","volume":"9","author":"Isaacs","year":"1998","journal-title":"Cell Growth Differ"},{"key":"10.1016\/j.clml.2019.08.011_bib39","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1006\/gyno.1996.0137","article-title":"Subcellular localization of accumulated p53 in ovarian cancer cells","volume":"61","author":"Runnebaum","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clml.2019.08.011_bib40","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/MCB.16.3.1126","article-title":"Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage","volume":"16","author":"Moll","year":"1996","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2019.08.011_bib41","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/89.20.1530","article-title":"Nuclear exclusion of wild-type p53 in immortalized human retinoblastoma cells","volume":"89","author":"Schlamp","year":"1997","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2019.08.011_bib42","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1093\/emboj\/19.22.6051","article-title":"Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuro-blastoma cells","volume":"19","author":"Sengupta","year":"2000","journal-title":"EMBO J"},{"key":"10.1016\/j.clml.2019.08.011_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0092-8674(02)01255-2","article-title":"Parc: a cytoplasmic anchor for p53","volume":"112","author":"Nikolaev","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.clml.2019.08.011_bib44","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/cas.12430","article-title":"Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma","volume":"105","author":"Yoshimura","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2019.08.011_bib45","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/15384101.2018.1480224","article-title":"Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death","volume":"17","author":"Marcus","year":"2018","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clml.2019.08.011_bib46","first-page":"229","article-title":"The expression of CRM1 is associated with prognosis in human osteosarcoma","volume":"21","author":"Yao","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clml.2019.08.011_bib47","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3892\/or.2014.3231","article-title":"Elevated expression of the nuclear export protein, Crm1 (exportin 1), associates with human oesophageal squamous cell carcinoma","volume":"32","author":"van der Watt","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clml.2019.08.011_bib48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clml.2019.08.011_bib49","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3324\/haematol.2013.093765","article-title":"Next-generation sequencing\u2013based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring","volume":"99","author":"Luthra","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.08.011_bib50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2012.219","article-title":"Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells","volume":"27","author":"Etchin","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.08.011_bib51","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood-2012-04-423160","article-title":"Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia","volume":"120","author":"Ranganathan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib52","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","article-title":"Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia","volume":"120","author":"Lapalombella","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.exphem.2012.09.002","article-title":"Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma","volume":"41","author":"Zhang","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2019.08.011_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.12231","article-title":"KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia","volume":"161","author":"Etchin","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.08.011_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2013.10.018","article-title":"New orally active proteasome inhibitors in multiple myeloma","volume":"38","author":"Allegra","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.08.011_bib56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.08.011_bib57","doi-asserted-by":"crossref","first-page":"13946","DOI":"10.1038\/s41598-017-14222-1","article-title":"Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells","volume":"7","author":"Body","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2019.08.011_bib58","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2015-01-621391","article-title":"Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia","volume":"125","author":"Hing","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib59","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-16-1580","article-title":"The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia","volume":"23","author":"Vercruysse","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.08.011_bib60","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2013-04-495374","article-title":"Preclinical and clinical efficacy of XPO1\/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias","volume":"122","author":"Walker","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib61","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.08.011_bib62","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2019.08.011_bib63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1046\/j.1365-2141.2003.04538.x","article-title":"Bcr-Abl upregulates cytosolic p21WAF-1\/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway","volume":"123","author":"Keeshan","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.08.011_bib64","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3324\/haematol.2017.185082","article-title":"Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial","volume":"103","author":"Zhang","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.08.011_bib65","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood-2012-08-447581","article-title":"Prognostic impact and targeting of CRM1 in acute myeloid leukemia","volume":"121","author":"Kojima","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib66","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/blood-2005-12-5148","article-title":"Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia","volume":"108","author":"Kojima","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib67","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1111\/jcmm.13886","article-title":"Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1","volume":"22","author":"Luedtke","year":"2018","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.clml.2019.08.011_bib68","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.341.341","article-title":"Phase II results of ara-C and idarubicin in combination with the selective inhibitor of nuclear export (SINE) compound selinexor (KPT-330) in patients with relapsed or refractory AML","volume":"128","author":"Fiedler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib69","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood-2015-05-646240","article-title":"Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse","volume":"126","author":"Garg","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib70","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","article-title":"A\u00a0phase I clinical trial of single-agent selinexor in acute myeloid leukemia","volume":"129","author":"Garzon","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-017-0550-8","article-title":"A\u00a0phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2019.08.011_bib72","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1200\/JCO.2016.67.5066","article-title":"Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia","volume":"34","author":"Alexander","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.08.011_bib73","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbrc.2017.04.042","article-title":"Leptomycin B alters the subcellular distribution of CRM1 (exportin 1)","volume":"488","author":"Rahamani","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clml.2019.08.011_bib74","first-page":"1379","article-title":"Leptomycin: a specific inhibitor of protein nuclear export","volume":"44","author":"Yoshida","year":"1999","journal-title":"Tanpakusshitsu Kakusan Loso"},{"key":"10.1016\/j.clml.2019.08.011_bib75","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1073\/pnas.1217203110","article-title":"Nuclear export inhibition through covalent coniugation and hydrolysis of leptomycin B by CRM1","volume":"110","author":"Sun","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2019.08.011_bib76","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1182\/blood-2011-01-333138","article-title":"CBS9106 is a novel reversible oral CRM1 with CRM1 degrading activity","volume":"118","author":"Sakakibara","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib77","first-page":"1217","article-title":"Consensus induced fit docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors","volume":"26","author":"Kalid","year":"2012","journal-title":"J\u00a0Comp Mol Des"},{"key":"10.1016\/j.clml.2019.08.011_bib78","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/leu.2016.136","article-title":"Next-generation XPO1 inhibitor shows improved efficacy and in\u00a0vivo tolerability in hematological malignancies","volume":"30","author":"Hing","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.08.011_bib79","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pharmthera.2017.09.001","article-title":"Immunoproteasome-selective and non-selective inhibitors: a promising approach for the treatment of multiple myeloma","volume":"182","author":"Ettari","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clml.2019.08.011_bib80","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ejh.12107","article-title":"Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma","volume":"90","author":"Allegra","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.08.011_bib81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0609.2010.01558.x","article-title":"Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors","volume":"86","author":"Allegra","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.08.011_bib82","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.critrevonc.2015.06.003","article-title":"Vaccination of multiple myeloma: current strategies and future prospects","volume":"96","author":"Allegra","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2019.08.011_bib83","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bcmd.2016.11.001","article-title":"Adoptive immunotherapy for hematological malignancies: current status and new insights in chimeric antigen receptor T cells","volume":"62","author":"Allegra","year":"2016","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.clml.2019.08.011_bib84","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","article-title":"Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.08.011_bib85","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1158\/0008-5472.CAN-09-0484","article-title":"Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition","volume":"69","author":"Turner","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2019.08.011_bib86","first-page":"614","article-title":"CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in\u00a0vitro and ex\u00a0vivo","volume":"4","author":"Turner","year":"2013","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.clml.2019.08.011_bib87","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.463.463","article-title":"XPO1 inhibition by Selinexor synergizes with BCR inhibition, blocks tumor growth and prolongs survival in a bioluminescent animal model of primary central nervous system lymphoma","volume":"128","author":"Crespo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib88","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.3324\/haematol.2017.181636","article-title":"Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement","volume":"103","author":"Bobillo","year":"2018","journal-title":"Haematologica"},{"issue":"15 suppl","key":"10.1016\/j.clml.2019.08.011_bib89","article-title":"A\u00a0phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL)","volume":"32","author":"Gutierrez","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.08.011_bib90","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-016-0304-z","article-title":"Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors","volume":"9","author":"Turner","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2019.08.011_bib91","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1182\/blood.V128.22.3298.3298","article-title":"Synergistic anti-tumor effect of KPT-8602, a second generation selective inhibitor of nuclear export (SINE) compound, and panobinostat, a pan-histone deacetylase (HDAC) inhibitor in multiple myeloma","volume":"128","author":"Argueta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib92","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids: mechanisms of action in health and disease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.clml.2019.08.011_bib93","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1182\/blood.V124.21.4773.4773","article-title":"Selinexor demonstrates marked synergy with dexamethasone (Sel-Dex) in preclinical models and in patients with heavily pretreated refractory multiple myeloma (MM)","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib94","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1182\/blood.V126.23.3683.3683","article-title":"Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows synergistic anti-tumor activity in combination with dexamethasone characterized by specific pattern of gene expression in multiple myeloma (MM)","volume":"126","author":"Kashyap","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib95","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1128\/MCB.24.10.4294-4308.2004","article-title":"Visualization of Myc\/Max\/Mad family dimers and the competition for dimerization in living cells","volume":"24","author":"Grinberg","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2019.08.011_bib96","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2016.34.15_suppl.8013","article-title":"Phase I trial of the combination of selinexor, liposomal doxorubicin and dexamethasone for relapsed and refractory multiple myeloma","volume":"34","author":"Baz","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.08.011_bib97","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.08.011_bib98","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood.V128.22.973.973","article-title":"Final results of phase 1 MMRC trial of selinexor, carfilzomib, and dexamethasone in relapsed\/refractory multiple myeloma (RRMM)","volume":"128","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib99","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood.V128.22.3330.3330","article-title":"Selinexor shows synergy in combination with pomalidomide and low dose dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib100","first-page":"3134","article-title":"Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with refractory multiple myeloma","volume":"130","author":"Cornell","year":"2017","journal-title":"Blood"},{"author":"Katz","key":"10.1016\/j.clml.2019.08.011_bib101"},{"key":"10.1016\/j.clml.2019.08.011_bib102","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2012.074781","article-title":"Selective inhibitors of nuclear export for the treatment of non-Hodgkin\u2019s lymphomas","volume":"98","author":"Azmi","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.08.011_bib103","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","article-title":"XPO1 inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of I\u03baB","volume":"17","author":"Ming","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"15 suppl","key":"10.1016\/j.clml.2019.08.011_bib104","article-title":"BGB-3111 is a novel and highly selective Bruton\u2019s tyrosine kinase (BTK) inhibitor","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2019.08.011_bib105","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2018.214759","article-title":"The BTK inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents","volume":"104","author":"Tarantelli","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.08.011_bib106","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/leu.2014.9","article-title":"Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells","volume":"28","author":"Zhong","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.08.011_bib107","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1756-8722-6-40","article-title":"Novel agents and biomarkers for acute lymphoid leukemia","volume":"6","author":"Zhao","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2019.08.011_bib108","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1182\/blood-2005-05-2123","article-title":"BCR-ABL nuclear entrapment kills human CML cells: ex\u00a0vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B","volume":"107","author":"Aloisi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib109","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41420-018-0049-2","article-title":"KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to imatinib","volume":"4","author":"Nie","year":"2018","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.clml.2019.08.011_bib110","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/leu.2015.194","article-title":"Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice","volume":"30","author":"Etchin","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.08.011_bib111","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2019.08.011_bib112","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-15-2885","article-title":"XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase IIalpha to the nucleus","volume":"22","author":"Ranganathan","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"pt 14","key":"10.1016\/j.clml.2019.08.011_bib113","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1242\/jcs.01147","article-title":"Human topoisomerase IIalpha nuclear export is mediated by two CRM-1\u2013dependent nuclear export signals","volume":"117","author":"Turner","year":"2004","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.clml.2019.08.011_bib114","first-page":"2129","article-title":"Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line","volume":"55","author":"Mirski","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2019.08.011_bib115","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/0008-5472.CAN-08-0858","article-title":"Identification of nuclear export inhibitors with potent anticancer activity in\u00a0vivo","volume":"69","author":"Mutka","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2019.08.011_bib116","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib117","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1002\/cncr.27396","article-title":"Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab","volume":"118","author":"Akyurek","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.08.011_bib118","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib119","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ajh.24451","article-title":"Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma","volume":"91","author":"Jardin","year":"2016","journal-title":"Am J Hematol"},{"issue":"15 suppl","key":"10.1016\/j.clml.2019.08.011_bib120","article-title":"A\u00a0phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed\/refractory acute myeloid leukemia (AML)","volume":"32","author":"Yee","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.08.011_bib121","article-title":"Phase I trial of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with advanced acute myelogenous leukemia (AML)","volume":"122","author":"Savona","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib122","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1651.1651","article-title":"phase 1 clinical trial of selinexor in combination with decitabine in patients with newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"128","author":"Bhatnagar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib123","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4040.4040","article-title":"A\u00a0phase I study of selinexor in combination with daunorubicin and cytarabine in patients with newly diagnosed poor-risk acute myeloid leukemia","volume":"128","author":"Sweet","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2019.08.011_bib124","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1182\/blood.V130.Suppl_1.816.816","article-title":"Selinexor in combination with cladribine, cytarabine and G-CSF for relapsed or refractory AML","volume":"130","author":"Uy","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2019.08.011_bib125","article-title":"Selinexor maintenance is feasible and tolerable after allogeneic stem cell transplant (allo-SCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)","volume":"130","author":"Liu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib126","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Abdul Razak","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.08.011_bib127","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2016-11-752840","article-title":"Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis","volume":"130","author":"Machlus","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib128","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nchembio.925","article-title":"Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles","volume":"8","author":"Serafimova","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.clml.2019.08.011_bib129","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2174\/1389450111314100002","article-title":"Nuclear export mediated regulation of microRNAs: potential target for drug intervention","volume":"14","author":"Muqbil","year":"2013","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.clml.2019.08.011_bib130","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V122.21.820.820","article-title":"Molecular mechanisms of inhibition of ribosomal biogenesis and translational flux by the selective inhibitor of nuclear export (SINE) XPO1\/CRM1 antagonist KPT-185 in mantle cell lymphoma","volume":"122","author":"Tabe","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.011_bib131","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.V122.21.3165.3165","article-title":"XPO1 inhibition disrupts ribosomal subunits assembly and induces multiple myeloma (MM) cell death","volume":"122","author":"Tagoug","year":"2013","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019313813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019313813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:37Z","timestamp":1761870817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019313813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":131,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S2152265019313813"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.08.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}